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Background: Rikkunshito is a traditional Japanese medicine that has been widely prescribed for patients with
various gastrointestinal symptoms. Recently, the prokinetic effects of Rikkunshito in patients with a variety of
diseases have attracted attention in Japan. The prokinetic effects of Rikkunshito are believed to result from an
increase of active ghrelin, which is most abundant in the stomach and which has a gastrokinetic function. The aim
of the present pilot study was to investigate the effects of Rikkunshito on intragastric enteral feeding and plasma
ghrelin levels in critically ill patients.
Methods: The study population consisted of critically ill patients who were projected to require intragastric tube
feeding for more than 7 days. The patients were prospectively assigned to one of two treatment groups and were
randomized to receive either Rikkunshito (2.5 g) or metoclopramide (10 mg) every 8 h. All patients received
standard enteral nutrition. Patients in both groups were begun on intragastric tube feeding according to our
institution’s feeding protocol.
Results: All patients were undergoing mechanical ventilation at the time of enrollment. The portions of enteral
nutrition provided to the target amount and the quantity of gastric discharge were not statistically significantly
different between the two groups. The Rikkunshito group reached 50% of the target amount of enteral feeding
significantly earlier than the metoclopramide group, although the proportion of patients in whom enteral feeding
was successful did not differ significantly between the two groups. Patients in the Rikkunshito group showed
significantly higher plasma levels of active ghrelin compared to those in the metoclopramide group.
Conclusions: The administration of Rikkunshito increased the plasma level of active ghrelin, and induced prokinetic
effects that were greater than those observed following treatment with metoclopramide in critically ill patients.
Trial registration: UMIN00000356
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Nutritional support is an important treatment for critic-
ally ill patients. Enteral support is preferred to parenteral
support, particularly in patients with prolonged inten-
sive care admissions [1]. However, gastrointestinal mo-
tility is frequently impaired in critically ill patients, and* Correspondence: mineji@dream.com
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unless otherwise stated.up to 50% of these patients are unable to tolerate enteral
feeding [2].
Intolerance of intragastric enteral feeding is usually
managed either by a change in the feeding route or by
pharmacological interventions [3]. While various proki-
netic drugs are available, few have been fully studied in
critically ill patients. Metoclopramide and erythromycin
have been studied in critical care settings [4]. Metoclo-
pramide improves gastric motility in critically ill patients
[4]. Erythromycin, a macrolide antibiotic, also acts as a
motilin receptor agonist and stimulates gastric motilityral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proves gastric emptying in critically ill patients [5-8].
Rikkunshito, a traditional Japanese medicine (Kampo),
has been widely prescribed for patients with various gas-
trointestinal symptoms. Rikkunshito is extracted from a
mixture of Glycyrrhizae radix (4.7%), Zingiberis rhizoma
(2.3%), Atractylodis lanceae rhizoma (18.6%), Zizyphi
fructus (9.3%), Aurantii nobilis pericarpium (9.3%), Gin-
seng radix (18.6%), Pinelliae tuber (18.6%), and Hoelen
(18.6%). Recently, the prokinetic activity of Rikkunshito
has attracted increased interest for the treatment of vari-
ous diseases in Japan [9-14]. In patients with gastroesoph-
ageal reflux disease and functional dyspepsia, Rikkunshito
improves clinical symptoms [9-12], gastric emptying [11],
and esophageal acid clearance [9]. Additionally, in patients
with persistent dyspepsia following gastrointestinal sur-
gery, Rikkunshito improves both dyspeptic symptoms
and gastric electrical activity [13]. Several flavonoids in
Rikkunshito have serotonin 2B/2C receptor antagonist
activity and accelerate active ghrelin release [15,16]. These
clinical effects were related to an increase in plasma ghre-
lin levels following Rikkunshito administration [12,15,17].
However, no data are currently available on the use of ei-
ther ghrelin or Rikkunshito to improve the tolerance of
intragastric enteral feeding in critically ill patients [3].
This study aimed to investigate the effect of Rikkunshito
on the tolerance of intragastric enteral feeding and plasma
ghrelin levels in critically ill patients. This single-center,
double-blind, randomized controlled trial is a pilot study
to evaluate the utility of Rikkunshito in comparison with
metoclopramide in the critical care setting.
Methods
The present study was approved by the Institutional
Review Board of Hokkaido University Hospital and was
registered as UMIN00000356 with the University Hospital
Medical Information Network (UMIN) Clinical Trials
Registry. The study population consisted of critically ill
patients who were projected to require intragastric tube
feeding for more than 7 days. Informed consent was ob-
tained from the family members of the patients. Patients
were excluded from the study for the following reasons:
(1) age less than 18 years, (2) contraindications to the
use of Rikkunshito or metoclopramide, or (3) use of
Rikkunshito or metoclopramide prior to inclusion in
the present study.
After enrollment in the current study, patients were
prospectively assigned to one of two treatment groups and
were randomized to receive either Rikkunshito (TJ-43,
Tsumura & Co., Tokyo, Japan) or metoclopramide
(Primperan, Astellas Pharma Inc., Tokyo, Japan). All
researchers involved in caring for the patients and collec-
ting the data were blinded to the agents the patients re-
ceived during the study period. In the Rikkunshito group,2.5 g of Rikkunshito was administered intragastrically
every 8 h via the feeding tube, while patients in the meto-
clopramide group received 10 mg of metoclopramide by
the same route and with the same frequency. All pa-
tients received standard enteral nutrition (1 mL = 1 kcal)
(Haine®, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan).
Patients in both groups were begun on intragastric tube
feeding according to our feeding protocol. The enteral
feeding was initiated at a rate of 20 mL/h. Every 4 h, all re-
sidual gastric discharge was suctioned and measured. If
the volume of gastric discharge was ≤100 mL, the full vol-
ume was returned to the patient, and the feeding rate was
increased by 20 mL/h. The feeding rate was not increased
over the target rate. If the volume of gastric discharge
was >100 mL, only 100 mL was returned to the patient,
and the enteral feeding was continued with no change in
rate. When a volume greater than 100 mL of gastric dis-
charge was observed on two consecutive measurements,
the feeding rate was decreased by 20 mL/h. The target
amount of calories and feeding rate were predetermined
by referencing basal energy expenditure based on the
Harris-Benedict equation [18]. The observation period
was defined as either the time from the start of feeding
until gastric feeding was no longer required or 10 days
after enrollment in the current study. During the period of
observation, the following treatments were prohibited: (1)
the use of other prokinetic drugs (erythromycin, mosa-
pride, domperidone, etc.) or (2) switch to intrajejunal
tube feeding. Successful enteral feeding was defined as
achievement of the target amount on two successive days.
Achievement of 50% of the target amount of enteral feed-
ing was defined as achieving 50% of the target amount of
enteral feeding on two successive days.
At the beginning and end of the observation period,
blood samples were collected from the patients in
tubes containing aprotinin and EDTA-2Na (LSI Medience
Corporation, Tokyo, Japan). The blood samples were im-
mediately centrifuged at 4°C. Plasma was acidified with
1 mol/L HCl (1/10 volume) and stored at −80°C until
measurement of ghrelin levels. The levels of active ghrelin
and desacyl ghrelin (inactive ghrelin) were measured with
commercial enzyme-linked immunosorbent assay (ELISA)
kits (Active Ghrelin ELISA Kit and Desacyl Ghrelin ELISA
Kit, SCETI KK, Tokyo, Japan). The primary endpoint of
the study was the success rate of the enteral feeding. The
secondary endpoints were the changes in the plasma levels
of active ghrelin and desacyl ghrelin.
All measurements are expressed as the mean ± standard
deviation (SD). The SPSS 15.0J statistical software package
(SPSS Inc., Chicago, IL, USA) was used for all statis-
tical analyses. Comparisons between the two groups were
made using Student’s t-test, the chi-square test, or two-
way repeated measures analysis of variance (ANOVA).
The Kaplan-Meier method and the log-rank test were
Figure 1 The portion of enteral nutrition provided to the
patients. No differences were observed between the two groups
during the observation period. Open circle, metoclopramide
group; closed circle, Rikkunshito group. Error bars show standard
deviation (SD).
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tween the two groups. A value of P < 0.05 was considered
to be statistically significant.
Results
Twenty-three patients were enrolled in the current study.
All patients were undergoing mechanical ventilation at
the time of enrollment. Thirteen patients were assigned to
the metoclopramide group, and 10 patients were assigned
to the Rikkunshito group. The characteristics of the pa-
tients in the two groups were well matched (Table 1). Nei-
ther the portions of enteral nutrition provided to the
patients (Figure 1) nor the quantity of gastric discharge
(Figure 2) differed significantly between the two groups.
The proportion of patients in whom enteral feeding was
successful also did not significantly differ between the two
groups (Figure 3). However, the Rikkunshito group
reached 50% of the target amount of enteral feeding
significantly earlier than the metoclopramide group
(P = 0.004) (Figure 4). No complications related to the
enteral feeding were observed in either group. The plasma
levels of active ghrelin and desacyl ghrelin are presented
in Table 2. The increase in the active ghrelin concentra-
tion following treatment was larger in the RikkunshitoTable 1 Characteristics of the patients
Metoclopramide Rikkunshito P
n = 13 n = 10
Age (years) 75 ± 11 70 ± 13 0.289
Sex (male/female) 8/5 5/5 0.685
Height (cm) 163 ± 9 162 ± 9 0.841
Weight (kg) 58.8 ± 10.8 60.4 ± 12.1 0.770
Body surface area (m2) 1.63 ± 0.16 1.64 ± 0.20 0.914
APACHE II score 28 ± 6 29 ± 10 0.774
Reason for admission to
the ICU







Days of enrollment after
admission to the ICU
3.5 ± 1.5 3.0 ± 2.3 0.563
C-reactive protein 8.3 ± 7.5 5.6 ± 6.7 0.385
Basal energy expenditure
(kcal/day)
1,219 ± 161 1,255 ± 239 0.703
Target volume of enteral
feeding (mL/h)
46.7 ± 7.8 51.0 ± 12.9 0.341
Observational period (day) 9.3 ± 2.2 9.8 ± 0.6 0.430
APACHE Acute Physiology and Chronic Health Evaluation, ICU intensive
care unit.group than in the metoclopramide group (P = 0.023). The
changes in the desacyl ghrelin concentrations did not sig-
nificantly differ between the two groups during the obser-
vation period.
Discussion
The present pilot study is the first randomized con-
trolled trial to evaluate the utility of Rikkunshito for en-
teral feeding in the critical care setting. The portions of
enteral nutrition provided to the target amount and the
quantity of gastric discharge did not significantly differFigure 2 The volume of gastric discharge. No differences were
observed between the two groups during the observation period.
Open bar, metoclopramide group; closed bar, Rikkunshito group.
Error bars show standard deviation (SD).
Figure 3 The proportions of successful enteral feeding. No
differences were observed between the two groups during the
observation period.
Table 2 Plasma levels of ghrelin
Metoclopramide Rikkunshito P
n = 13 n = 10
Active ghrelin (fmol/mL)
Pre-treatment (day 0) 20.8 ± 17.1 29.2 ± 18.0 0.023
Post-treatment (day 10) 32.3 ± 37.9 60.4 ± 56.8
Desacyl ghrelin (fmol/mL)
Pre-treatment (day 0) 62.5 ± 27.5 77.9 ± 44.4 0.784
Post-treatment (day 10) 115.3 ± 63.8 122.8 ± 80.6
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50% of the target amount of enteral feeding significantly
earlier than the metoclopramide group, although the pro-
portion of patients in whom enteral feeding was successful
did not differ significantly between the two groups.
Significant increases in the plasma active ghrelin levels
were observed in the Rikkunshito group in comparison
to the metoclopramide group. Previous studies haveFigure 4 The proportions achieving 50% of the target amount
of enteral feeding. The Rikkunshito group reached 50% of the
target amount of enteral feeding significantly earlier than the
metoclopramide group (P = 0.004).found that metoclopramide led to improvement in gas-
tric emptying in critically ill patients with an intolerance
of enteral feeding, compared to placebo [4,19]. The pre-
sent study, however, included patients with and without
an intolerance of normal enteral feeding, because pa-
tients were enrolled at the beginning of the enteral feed-
ing period. Moreover, the present pilot study had a small
sample size. Therefore, this study may have been under-
powered to detect differences between Rikkunshito and
metoclopramide in the proportion of successful enteral
feeding.
Ghrelin, a growth hormone-releasing acylated peptide,
is a ligand for the growth hormone secretagogue recep-
tor (GHS-R) in stomach tissue [20]. However, ghrelin
and motilin, as well as GHS-R and the motilin receptor,
are structurally related [21]. Furthermore, ghrelin is most
abundant in the stomach, while GHS-R is present in both
the stomach and other organs [21]. Therefore, ghrelin, like
motilin, has been concluded to have a gastrokinetic func-
tion [3,21]. In functional dyspepsia, the plasma active
ghrelin levels are related to gastric emptying and clinical
symptoms [12,22]. In diabetic gastroparesis patients, intra-
venous ghrelin administration enhances gastric emptying
[23]. The prokinetic effects of active ghrelin include an in-
duction of premature phase III activity and a prolonged
increase in proximal gastric tone [24]. These are direct ef-
fects, not mediated through the release of other gas-
trointestinal hormones [24]. In this study, Rikkunshito
administration both accelerated active ghrelin release and
improved gastrokinetic function.
Although metoclopramide is a traditional prokinetic
drug, its effects on the release of active ghrelin are un-
clear. Metoclopramide acts as a dopamine receptor an-
tagonist, a serotonin antagonist (serotonin 3 receptor),
and a serotonin partial agonist (serotonin 4 receptor)
[25]. The drug leads to the release of acetylcholine from
gut neurons, antagonizing the inhibitory effects of dopa-
mine on gastrointestinal motility [3]. A previous study
indicated that the cholinergic system controlled the re-
lease of ghrelin and that acetylcholine increased the
plasma concentration of active ghrelin [26,27]. Metoclo-
pramide was not found to activate the secretion of ghrelin
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the prokinetic effects of metoclopramide observed in the
current study are related to ghrelin secretion.
Conclusions
In the present study, the administration of Rikkunshito
led to increased plasma levels of active ghrelin and in-
duced prokinetic effects that were greater than those ob-
served following treatment with metoclopramide in
critically ill patients. Although Rikkunshito appears to be
an effective stimulator of active ghrelin secretion and
improves gastrokinetic function in the critical care set-
ting, further investigations with a larger sample size will
be required to clarify the effects of Rikkunshito in pa-
tients with an intolerance of enteral feeding.
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